AR016672A1 - Ligandos del receptor h3 del tipo fenil-alquil-imidazoles, composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de unmedicamento - Google Patents
Ligandos del receptor h3 del tipo fenil-alquil-imidazoles, composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de unmedicamentoInfo
- Publication number
- AR016672A1 AR016672A1 ARP980105622A ARP980105622A AR016672A1 AR 016672 A1 AR016672 A1 AR 016672A1 AR P980105622 A ARP980105622 A AR P980105622A AR P980105622 A ARP980105622 A AR P980105622A AR 016672 A1 AR016672 A1 AR 016672A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- phenyl
- manufacture
- pharmaceutical composition
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 abstract 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96634497A | 1997-11-07 | 1997-11-07 | |
| US12971198A | 1998-08-05 | 1998-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016672A1 true AR016672A1 (es) | 2001-07-25 |
Family
ID=26827847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105622A AR016672A1 (es) | 1997-11-07 | 1998-11-06 | Ligandos del receptor h3 del tipo fenil-alquil-imidazoles, composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de unmedicamento |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1028947B8 (enExample) |
| JP (1) | JP2001522835A (enExample) |
| KR (1) | KR20010031724A (enExample) |
| CN (1) | CN1130349C (enExample) |
| AR (1) | AR016672A1 (enExample) |
| AT (1) | ATE219062T1 (enExample) |
| AU (1) | AU1296699A (enExample) |
| CA (1) | CA2308586A1 (enExample) |
| CO (1) | CO5011065A1 (enExample) |
| DE (1) | DE69806042T2 (enExample) |
| ES (1) | ES2174510T3 (enExample) |
| HU (1) | HUP0004292A3 (enExample) |
| IL (1) | IL135729A0 (enExample) |
| NZ (1) | NZ504124A (enExample) |
| PE (1) | PE134399A1 (enExample) |
| TW (1) | TW421645B (enExample) |
| WO (1) | WO1999024405A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| EP1373251A2 (en) | 2001-03-13 | 2004-01-02 | Schering Corporation | Non-imidazole compounds as histamine h3 antagonists |
| PL374758A1 (en) * | 2002-10-24 | 2005-10-31 | Merck Patent Gmbh | Methylene urea derivatives |
| WO2006076706A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
| EP1749523A1 (en) * | 2005-07-29 | 2007-02-07 | Neuropharma, S.A. | GSK-3 inhibitors |
| WO2007035703A1 (en) | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| AU2013307688A1 (en) * | 2012-08-29 | 2015-04-09 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| NZ330898A (en) * | 1993-11-15 | 2000-01-28 | Schering Corp | Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation |
| FR2732017B1 (fr) * | 1995-03-21 | 2000-09-22 | Inst Nat Sante Rech Med | Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques |
| PL191073B1 (pl) * | 1996-08-16 | 2006-03-31 | Schering Corp | Zastosowanie kombinacji antagonistów receptorów histaminowych H1 i H3 |
-
1998
- 1998-11-05 EP EP98956442A patent/EP1028947B8/en not_active Expired - Lifetime
- 1998-11-05 AT AT98956442T patent/ATE219062T1/de not_active IP Right Cessation
- 1998-11-05 HU HU0004292A patent/HUP0004292A3/hu unknown
- 1998-11-05 KR KR1020007004787A patent/KR20010031724A/ko not_active Withdrawn
- 1998-11-05 AU AU12966/99A patent/AU1296699A/en not_active Abandoned
- 1998-11-05 DE DE69806042T patent/DE69806042T2/de not_active Expired - Fee Related
- 1998-11-05 CN CN98812981A patent/CN1130349C/zh not_active Expired - Fee Related
- 1998-11-05 CA CA002308586A patent/CA2308586A1/en not_active Abandoned
- 1998-11-05 IL IL13572998A patent/IL135729A0/xx unknown
- 1998-11-05 NZ NZ504124A patent/NZ504124A/xx unknown
- 1998-11-05 TW TW087118436A patent/TW421645B/zh not_active IP Right Cessation
- 1998-11-05 JP JP2000520419A patent/JP2001522835A/ja not_active Ceased
- 1998-11-05 WO PCT/US1998/023223 patent/WO1999024405A1/en not_active Ceased
- 1998-11-05 ES ES98956442T patent/ES2174510T3/es not_active Expired - Lifetime
- 1998-11-06 AR ARP980105622A patent/AR016672A1/es unknown
- 1998-11-06 CO CO98065582A patent/CO5011065A1/es unknown
- 1998-11-06 PE PE1998001070A patent/PE134399A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0004292A2 (hu) | 2001-11-28 |
| EP1028947B1 (en) | 2002-06-12 |
| DE69806042D1 (de) | 2002-07-18 |
| CA2308586A1 (en) | 1999-05-20 |
| NZ504124A (en) | 2002-10-25 |
| KR20010031724A (ko) | 2001-04-16 |
| WO1999024405A1 (en) | 1999-05-20 |
| CN1285822A (zh) | 2001-02-28 |
| ES2174510T3 (es) | 2002-11-01 |
| TW421645B (en) | 2001-02-11 |
| HK1025968A1 (en) | 2000-12-01 |
| JP2001522835A (ja) | 2001-11-20 |
| EP1028947B8 (en) | 2004-01-28 |
| CO5011065A1 (es) | 2001-02-28 |
| CN1130349C (zh) | 2003-12-10 |
| ATE219062T1 (de) | 2002-06-15 |
| EP1028947A1 (en) | 2000-08-23 |
| DE69806042T2 (de) | 2003-01-23 |
| HUP0004292A3 (en) | 2001-12-28 |
| AU1296699A (en) | 1999-05-31 |
| PE134399A1 (es) | 2000-01-10 |
| IL135729A0 (en) | 2001-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7718674B2 (en) | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine | |
| DE60017898T2 (de) | Neuartige heterocyclische carboxamidderivate | |
| US8367733B2 (en) | Infiltration of capsaicin into surgical sites and open wounds | |
| US8420600B2 (en) | Injectable capsaicin | |
| JP4787148B2 (ja) | 新規アリールピペラジニル化合物 | |
| US20060148903A1 (en) | Capsaicinoid gel formulation and uses thereof | |
| WO2006037047A2 (en) | The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents | |
| KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
| ATE316076T1 (de) | Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| JP2004518653A (ja) | 不安障害を治療する方法 | |
| AR029190A1 (es) | Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco | |
| TW200526631A (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
| ATE143806T1 (de) | Verbesserungen von oder in bezug auf exzitatorische aminosäurenrezeptorantagonisten | |
| WO2006125180B1 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| DE69622246T2 (de) | Neue Naphthamid-Derivate und ihre therapeutische Verwendung als D3-Rezeptor Agonisten | |
| CN112638386A (zh) | 异喹啉-类固醇缀合物及其用途 | |
| ES2223143T3 (es) | Derivados de 5-(2-imidazolinilamino)-bencimidazol, preparacion y uso de los mismos como agonistas de adrenorreceptores alfa con estabilidad metabolica mejorada. | |
| CN115710233A (zh) | Cftr调节剂及其使用方法 | |
| AR016672A1 (es) | Ligandos del receptor h3 del tipo fenil-alquil-imidazoles, composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de unmedicamento | |
| JPH09511483A (ja) | α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物 | |
| KR950701623A (ko) | 치환된 헥사하이드로벤조페난트리딘 | |
| DE69228042T2 (de) | Naphthamide, Verfahren zur Herstellung und ihre therapeutische Anwendung | |
| DE69522764T2 (de) | Verwendung vom einem Bicycloheptan-Derivat | |
| DE68915595T2 (de) | Verwendung von Isoxazolinonen als cerebro-aktive Medikamente. | |
| EA200501040A1 (ru) | Замещенные производные 1-пиперидин-3-ил-4-пиперидин-4-илпиперазина и их применение в качестве антагонистов нейрокинина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |